First AD

Second AD

Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.

Novel Combination Therapies in First-Line CLL: Potential Impact of Treatment Sequencing

Video content above is prompted by the following:

Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL 

OncLive Insights

Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.